SCHEMBL591561

SCHEMBL591561

[O][C@@H]1CCCOC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11516730 1.00
SCHEMBL302739 1.00
SCHEMBL524702 0.92
SCHEMBL939613 0.81
SCHEMBL942278 0.81
SCHEMBL37819 0.81
SCHEMBL4356389 0.81
SCHEMBL524952 0.77
SCHEMBL19985099 0.69 ALDH1A1 (0.35)
SCHEMBL20886323 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-02 US disclosed
CN-112110944-B Compound and preparation method and application thereof 南京谷睿生物科技有限公司 2022-02-11 CN disclosed
WO-2020253352-A1 COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 南京谷睿生物科技有限公司 2020-12-24 WO disclosed
CN-112110944-A Compound and preparation method and application thereof 南京谷睿生物科技有限公司 2020-12-22 CN disclosed
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-08 US disclosed
EP-3524599-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Japan Tobacco Inc. (JP) 2019-08-14 EP disclosed
US-20180346449-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2018-12-06 US disclosed
EP-2698375-B1 TGR5 modulators and method of use thereof INTERCEPT PHARMACEUTICALS INC (US) 2018-02-21 EP disclosed
US-20180016295-A1 TGR5 Modulators and Methods of Use Thereof INTERCEPT PHARMACEUTICALS INC (US) 2018-01-18 US disclosed
EP-3199533-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Japan Tobacco Inc. (JP) 2017-08-02 EP disclosed
US-8410083-B2 23-substituted bile acids as TGR5 modulators and methods of use thereof INTERCEPT PHARMACEUTICALS, INC. (US) 2013-04-02 US disclosed
US-20120115832-A1 TGR5 Modulators and Methods of Use Thereof INTERCEPT PHARMACEUTICALS, INC. (US) 2012-05-10 US disclosed
US-8114862-B2 TGR5 modulators and methods of use thereof INTERCEPT PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
EP-2376519-A1 TGR5 MODULATORS AND METHOD OF USE THEREOF Intercept Pharmaceuticals, Inc. (US) 2011-10-19 EP disclosed
US-20110003782-A1 23-Substituted Bile Acids as TGR5 Modulators and Methods of Use Thereof INTERCEPT PHARMACEUTICALS, INC. 2011-01-06 US disclosed
US-20100152151-A1 TGR5 MODULATORS AND METHODS OF USE THEROF INTERCEPT PHARMACEUTICALS, INC. (US) 2010-06-17 US disclosed
WO-2010059853-A1 TGR5 MODULATORS AND METHOD OF USE THEREOF INTERCEPT PHARMACEUTICALS, INC. (US) 2010-05-27 WO disclosed
EP-2112995-A2 23-SUBSTITUTED BILE ACIDS AS TGR5 MODULATORS AND METHODS OF USE THEREOF Intercept Pharmaceuticals, Inc. (US) 2009-11-04 EP disclosed
WO-2008091540-A2 23-SUBSTITUTED BILE ACIDS AS TGR5 MODULATORS AND METHODS OF USE THEREOF INTERCEPT PHARMACEUTICALS, INC. (US) 2008-07-31 WO disclosed
EP-1947108-A1 TGR5 modulators and methods of use thereof Intercept Pharmaceuticals, Inc. (US) 2008-07-23 EP disclosed